BioCentury
ARTICLE | Finance

Ablynx's booster shot for U.S. access

Ablynx adds ADRs to increase U.S. investor access

September 15, 2014 7:00 AM UTC

Ablynx N.V. (Euronext:ABLX; Grey:ABYLY) has already put in the face time to build out a strong U.S. investor base, but the fact that not all U.S. funds can invest outside the country has led the antibody platform play to launch an American Depository Receipt (ADR) program that should boost investor access to the stock without adding to the biotech's reporting burdens.

CEO Edwin Moses told BioCentury that more than 25% of Ablynx's shareholder base is already in the U.S. Indeed, two of its major shareholders are U.S. funds, Biotech Value Fund and Perceptive Advisors, which hold about 5% and 4%, respectively...